MacroGenics to Present TAMARACK Phase 2 Data at ESMO 2024

MacroGenics, Inc., a biopharmaceutical company renowned for its innovative antibody-based cancer treatments, has announced a significant presentation at the upcoming European Society for Medical Oncology (ESMO) Congress. This event will be held in Barcelona, Spain, from September 13-17, 2024. The company will showcase Phase 2 data on their drug candidate, vobramitamab duocarmazine, aimed at treating metastatic castration-resistant prostate cancer (mCRPC).

On Sunday, September 15, 2024, MacroGenics will present the TAMARACK study, a randomized Phase 2 trial focusing on the efficacy of vobramitamab duocarmazine. This antibody-drug conjugate (ADC) targets B7-H3, a protein commonly overexpressed in mCRPC. The lead author for this presentation is Dr. Johann de Bono from the Royal Marsden Hospital Institute of Cancer Research in the UK. The poster session will be available from 9:00 a.m. to 5:00 p.m. Central European Summer Time (CEST).

The abstract presented at ESMO in May 2024 was based on data available until April 12, 2024. The upcoming poster will include updated data up to July 9, 2024. The presentation will cover critical safety and efficacy metrics, focusing on the primary endpoint: 6-month radiographic progression-free survival (rPFS). Although the median rPFS data is still immature and may evolve with additional events, this update will provide valuable insights into the drug's performance.

Interested parties can access the poster on September 15, 2024, via the "Events & Presentations" section in the Investor Relations area of MacroGenics' website.

In addition to the poster presentation, MacroGenics plans to host a conference call on Monday, September 16, 2024, at 8:00 a.m. Eastern Time. This call aims to discuss the TAMARACK data and offer a broader corporate update. Leading the call will be Dr. Scott Koenig, the President and CEO; Dr. Stephen Eck, the Senior Vice President for Clinical Development and Chief Medical Officer; and Jim Karrels, the Senior Vice President and Chief Financial Officer. 

Those interested in participating in the conference call are advised to register in advance. Upon registration, participants will receive an email with details on how to join the call, including a dial-in number and a unique passcode. A listen-only webcast will also be accessible through MacroGenics' website, with a recorded replay available for 30 days following the call.

MacroGenics is committed to the discovery, development, manufacturing, and commercialization of antibody-based therapeutics. The company's innovative pipeline is built on proprietary technologies that enhance the therapeutic application across various medical fields. Through strategic collaborations with global pharmaceutical and biotechnology firms, MacroGenics aims to advance its promising product candidates further.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!